Skip to main content
Fig. 1 | Infectious Agents and Cancer

Fig. 1

From: Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy)

Fig. 1

Vaccine immune response monitoring in previously infected and not previously infected cohorts of healthcare providers. For not infected subjects (n = 123): T0 = baseline pre-vaccination, T1 = 20 days after the first dose, T2 = 8 days after the second dose, T3 = 3 months after the second dose, T6 = 6 months after the second dose, T9 = 9 months after the second dose, T boost = 8 days after the administration of boost dose. For previously infected subjects (n = 27): T0 = baseline pre-vaccination after SARS-CoV-2 infection, T1 = 8 days after the unique dose, T2 = 1 month after the unique dose, T3 = 3 months after the unique dose, T6 = 6 months after the unique dose, T9 = 9 months after the unique dose, T boost = 8 days after the administration of a further boost dose. Orange lines: subjects previously infected with SARS-CoV-2. Yellow lines: subjects not previously infected and with T2 titers < 500.0 BAU/mL. Green lines: subjects not previously infected and with T2 titers < 1000.0 BAU/mL and ≥ 500.0 BAU/mL. Grey lines: subjects not previously infected and with T2 titers < 2000.0 BAU/mL and ≥ 1000.0 BAU/mL. Blue lines: subjects not previously infected and with T2 titers ≥ 2000.0 BAU/mL

Back to article page